Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06861010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 20, 2025 to Dec 20, 2026v4
  2. Primary completion date: Apr 20, 2025 to Dec 20, 2025 Completion date: Aug 20, 2025 to Dec 20, 2025v3 Show 1 more changeShow less
    • Completion date: Aug 20, 2025 to Dec 20, 2025
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 20, 2025 to Mar 1, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 20, 2025 to Mar 1, 2025
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Trial Details
NCT Number NCT06861010
Lead Sponsor Tanta University
Conditions Pancreatic Diseases
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov